Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an announcement.
Chimeric Therapeutics has secured a $2.5 million advance from Endpoints Capital against its anticipated FY25 R&D Tax Incentive. This funding will bolster the company’s financial position, supporting its clinical trial pipeline and general working capital. The agreement provides early access to funds, enhancing Chimeric’s operational capabilities and reinforcing its strategic positioning in the cell therapy industry.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is an Australian clinical-stage cell therapy company focused on developing innovative treatments for cancer. The company specializes in autologous CAR T cell therapies and allogeneic NK cell therapies, with a diversified portfolio targeting various oncology disease areas. Chimeric is committed to advancing its clinical-stage programs and bringing promising cell therapies to patients.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.08M
See more insights into CHM stock on TipRanks’ Stock Analysis page.